Search Results

Ligand Pharmaceuticals Incorporated announced that it has closed the transaction to acquire assets of Novan, Inc. following the offer it made on July 17, 2023.

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that it has made an offer to acquire the assets of Novan, Inc. (Nasdaq: NOVN) (“Novan”) for $15 million in cash and provide up to $15 million in DIP financing to Novan inclusive of a $3 million bridge loan already funded.

Novan, Inc., announced that its commercial subsidiary, EPI Health, will now unify under one brand name, Novan.

Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its first quarter 2023 financial results on Monday, May 15th.

Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that the U.S. Food and Drug Administration (“FDA”) accepted for filing Novan’s New Drug Application (“NDA”) seeking approval for berdazimer gel, 10.3% (SB206) for the treatment of molluscum contagiosum (“molluscum”).

Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its full year 2022 financial results on Thursday, March 30th.

Novan, Inc., announced that following an evaluation of its commercial and developmental stage assets, it has decided to sharpen its focus and resources on berdazimer gel, 10.3% and announced that it continues to explore strategic alternatives, with a focus on its commercial product portfolio and a sale or out-license of one or more of its commercial products.

Novan, Inc., announced that it will host a live audio webcast of the Company’s 2023 Annual Meeting of Stockholders being held on Tuesday, June 6, 2023 at 9:30 a.m. Eastern Time in a virtual format.

Novan, Inc., announced its financial and operating results for the first quarter ended March 31, 2023, and provided a corporate update.

Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), and MC2 Therapeutics today announced that results of a recently conducted survey to assess psoriasis patients’ topical treatment experience, expectations, and preferences have been published in the Journal of Drugs in Dermatology (JDD).